Home > Insider Trading > Filing (0001232524-15-000017)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1232524	Jazz Pharmaceuticals Plc	JAZZ	Pharmaceutical Preparations (2834)	981032470

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1394522	K Jeffrey Tobias	Connaught House, 1 Burlington Rd, Fl. 4 Dublin4 L2	Evp, R&D & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2015-02-10	5,000	$46.83	40,063	No	4	M	Direct
Ordinary Shares	Disposition	2015-02-10	3,000	$166.48	37,063	No	4	S	Direct
Ordinary Shares	Disposition	2015-02-10	2,000	$167.34	35,063	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Non-Qualified Stock Option (right to buy)	Disposition	2015-02-10	5,000	$0.00	5,000	$46.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,019		2022-08-08	No	4	M	Direct

Footnotes

Includes 123 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 28, 2014.
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.03 to $166.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.01 to $167.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
As of the date of this report, the remaining ordinary shares subject to this option are vested with respect to 2,682 shares and will vest with respect to 12,805 shares in equal monthly installments from March 9, 2015 to December 9, 2015 and with respect to 9,532 shares in equal monthly installments from January 9, 2016 to August 9, 2016.